Lithgow K, Siqueira I, Senthil L, Chew H S, Chavda S V, Ayuk J, Toogood A, Gittoes N, Matthews T, Batra R, Meade S, Sanghera P, Khan N, Ahmed S, Paluzzi A, Tsermoulas G, Karavitaki N
Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK.
Pituitary. 2020 Jun;23(3):258-265. doi: 10.1007/s11102-020-01034-2.
Highlight and characterize manifestations, diagnostic/management approaches and outcomes in a contemporary cohort of patients with pituitary metastases (PM) from a large European pituitary center-over 10 years.
Retrospective review of PM cases between 1/2009 and 12/2018. Clinical, laboratory, imaging data at PM detection and during follow-up were analysed.
18 cases were identified (14 females; median age at diagnosis 61.5 years). Most common primary malignancies were lung (39%) and breast (32%). Most frequent presenting manifestation was visual dysfunction (50%). Gonadotrophin, ACTH, TSH deficiency were diagnosed in 85%, 67%, 46% of cases, respectively; diabetes insipidus (DI) was present in 17%. 33% of cases were detected during investigation for symptoms unrelated to PM. PM management included radiotherapy (44%), transsphenoidal surgery (17%), transsphenoidal surgery and radiotherapy (6%) or monitoring only (33%). One-year survival was 49% with median survival from PM detection 11 months (range 2-47).
In our contemporary series, clinical presentation of PM has evolved; we found increased prevalence of anterior hypopituitarism, decreased rates of DI and longer survival compared with older literature. Increased availability of diagnostic imaging, improvements in screening and recognition of pituitary disease and longer survival of patients with metastatic cancer may be contributing factors.
对来自欧洲一家大型垂体中心超过10年的当代垂体转移瘤(PM)患者队列的表现、诊断/管理方法及预后进行重点描述和分析。
回顾性分析2009年1月至2018年12月期间的PM病例。分析PM确诊时及随访期间的临床、实验室及影像学数据。
共识别出18例患者(14例女性;诊断时的中位年龄为61.5岁)。最常见的原发恶性肿瘤为肺癌(39%)和乳腺癌(32%)。最常见的首发表现为视觉功能障碍(50%)。分别有85%、67%、46%的病例诊断为促性腺激素、促肾上腺皮质激素、促甲状腺激素缺乏;17%的病例存在尿崩症(DI)。33%的病例在调查与PM无关的症状时被发现。PM的管理包括放疗(44%)、经蝶窦手术(17%)、经蝶窦手术加放疗(6%)或仅进行监测(33%)。1年生存率为49%,从PM确诊起的中位生存期为11个月(范围2 - 47个月)。
在我们的当代系列研究中,PM的临床表现有所演变;与既往文献相比,我们发现垂体前叶功能减退的患病率增加,DI发生率降低,生存期延长。诊断性影像学检查的可及性增加、垂体疾病筛查和识别的改善以及转移性癌症患者生存期的延长可能是促成因素。